Relay Therapeutics Outperforms ReNeuron Group in Biotech Comparison

Got story updates? Submit your updates here. ›

ReNeuron Group (OTCMKTS:RNUGF) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but a comparison of the two shows Relay Therapeutics has stronger fundamentals and is favored by analysts. Relay Therapeutics has a higher consensus price target, more institutional ownership, and better financial metrics like net margins, return on equity, and return on assets compared to ReNeuron Group.

Why it matters

This analysis provides insight into the relative performance and growth potential of these two biotech companies, which could be useful for investors looking to allocate capital in the healthcare sector. The contrasting profiles of ReNeuron Group and Relay Therapeutics highlight the importance of evaluating a company's overall strength beyond just its share price volatility.

The details

ReNeuron Group has a beta of -0.6, indicating its share price is 160% less volatile than the S&P 500, while Relay Therapeutics has a beta of 1.55, making its share price 55% more volatile. In terms of profitability, Relay Therapeutics has higher net margins, return on equity, and return on assets compared to ReNeuron Group. Analysts also have a stronger consensus rating and see more potential upside for Relay Therapeutics, with a price target of $15.40 implying a 44% gain. Relay Therapeutics also has much higher institutional ownership at 97% versus just 4.3% for ReNeuron Group.

• The analysis was published on March 11, 2026.